BHST BHST
Company Profile ↓Company Overview
BHST (BHST) is a publicly traded company listed on with a market capitalization of $51.23M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 84.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $34.51M (+37.0% YoY); net profit $-11.13M.
- Trailing 12 Months Year-on-year growth — revenue +37.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 84.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 84.46% |
| 1 Year: | 37.00% |
Stock Price Performance
| 1 Year: | -70.53% |
| 6 Months: | -52.42% |
| 3 Months: | -46.32% |
| 1 Month: | -22.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 84.5% over 5 years.
CONS
- Trading 82.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 7.86M | 8.52M | 9.07M | 9.07M | 8.51M |
| Cost of Revenue | 3.27M | 3.43M | 3.50M | 3.84M | 3.47M |
| Gross Profit | 4.59M | 5.09M | 5.57M | 5.22M | 5.04M |
| Operating Expenses | 6.31M | 6.90M | 6.49M | 6.35M | 6.87M |
| Operating Income | -1.72M | -1.81M | -920.00K | -1.12M | -1.83M |
| EBITDA | -1.32M | -1.41M | -535.00K | -3.45M | -1.29M |
| Interest Expense | 581.00K | 2.23M | 1.53M | -1.61M | 875.00K |
| Pretax Income | -2.30M | -4.04M | -2.45M | -2.27M | -2.60M |
| Tax Provision | 38.00K | 39.00K | 63.00K | -64.00K | 46.00K |
| Net Income | -2.34M | -4.08M | -2.51M | -2.20M | -2.64M |
| Diluted EPS | -0.13 | -0.24 | -0.14 | - | -0.11 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 5.50M | 12.67M | 25.19M | 34.51M |
| Cost of Revenue | - | 4.28M | 7.04M | 11.25M | 14.03M |
| Gross Profit | - | 1.22M | 5.63M | 13.94M | 20.48M |
| Operating Expenses | - | 11.83M | 15.60M | 20.93M | 26.05M |
| Operating Income | - | -10.61M | -9.97M | -6.99M | -5.58M |
| EBITDA | - | -9.12M | -9.76M | -6.92M | -6.71M |
| Interest Expense | - | 1.40M | 1.96M | 4.74M | 2.72M |
| Pretax Income | - | -11.24M | -12.56M | -12.90M | -11.06M |
| Tax Provision | - | - | 0 | 8.00K | 76.00K |
| Net Income | - | -11.24M | -12.56M | -12.91M | -11.13M |
| Diluted EPS | - | -0.70 | -0.93 | -0.80 | -0.60 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 9.39M | 15.00M | 25.00M | 47.66M |
| Current Assets | - | 4.32M | 9.05M | 7.86M | 30.50M |
| Cash & Equivalents | - | 1.74M | 5.36M | 2.39M | 23.02M |
| Inventory | - | 1.38M | 2.47M | 3.65M | 4.56M |
| Receivables | - | 545.00K | 808.00K | 1.12M | 1.98M |
| Total Liabilities | - | 15.32M | 29.86M | 23.67M | 22.22M |
| Current Liabilities | - | 11.52M | 26.47M | 14.26M | 7.68M |
| Long Term Debt | - | - | - | - | 2.42M |
| Total Debt | - | 10.56M | 22.34M | 13.82M | 14.10M |
| Total Equity | - | -5.93M | -14.85M | 1.33M | 25.45M |
| Shares Outstanding | - | 13.16M | 13.68M | 17.33M | 22.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.24M | -8.52M | -6.68M | -7.23M |
| Investing Cash Flow | - | -1.26M | -1.47M | -3.03M | -2.37M |
| Financing Cash Flow | - | 8.14M | 13.56M | 6.78M | 30.19M |
| Capital Expenditure | - | -1.26M | -1.47M | -2.83M | -2.35M |
| Free Cash Flow | - | -10.50M | -10.00M | -9.52M | -9.58M |
| Net Change in Cash | - | -2.36M | 3.56M | -2.93M | 20.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 22.2% | 44.5% | 55.4% | 59.3% |
| Operating Margin % | - | -193.0% | -78.6% | -27.7% | -16.2% |
| Net Margin % | - | -204.4% | -99.1% | -51.3% | -32.3% |
| ROE % | - | 189.5% | 84.6% | -970.9% | -43.8% |
| ROCE % | - | 499.2% | 86.9% | -65.1% | -13.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHST
BioHarvest CEO to Join One-on-One Meetings at Boston Conference - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPb2lYWGZEdFhab1QwRVhSV0VSSzBEVU5tUUFFNlFSYl9kUVVmSm44eXJQd1hiQkRBQnBWc1hDcHctNUFsNFJFU1d1U2JzbjNwOG04U1NjdFY2VTFHbld3dGxLR054T2xLLWV4eTlhXzNjWERsd3ZIZTNZWWh1T1Q3VUhhS2hid19Ic3BnWW…
What Does BioHarvest Sciences Inc.'s (NASDAQ:BHST) Share Price Indicate? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTFBBNTZJT2pEcXhINWFCcThSbmhlVGZuVkZSNjhVMzhPaWxPVFYxMzRRb2daMEl4NDBLXzE0ajJfMEFubzFQT3FWNW9DOXZNZy1NWFBDVE9jSVczcFR5a2JDVkVvUHgzZjdXT29SOVhVcnNLbWg0R0hJdGRNektfZXMySVVibEFySnFxS1…
Discipline and Rules-Based Execution in BHST Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNMC1DeUg2MElUV3kteWdNUHdUTHg3a2dXMmtNQWpMajFzT1U1SGpSUmdmbU1FX3hxeDY1cDJHSTdjYjd0MW5FZVpHbmJJbW45ZFQ1eGRqSmtvQzBtVjZYZjg1c20zcWk2Zkt4TTNVNGFIcmhKR3lLVGZtUG03QWVZVE9yMVR0WG14S3pqTE…
BHST|Bioharvest Sciences Inc|Price:2.270|Chg%:+0.110 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9ncThEOUtGOG1VaEV2dTkzTE12aXhVXzVQWEQ1MXRLQWx5VE5hb0ItaE42R2MzQVYwSkNlLUtHbV9uT0JvSllEalNZWjBVTzNLaGphOHNwUm5YX1lEWjI2QWI3WndYNzByM1Jra3JR?oc=5" target="_blank">BHST|Bioharvest Sci…
BioHarvest Sciences (NASDAQ: BHST) joins Canaccord 46th Growth Conference - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQWlBDeFd3NEJVdFNHRXlvRXBjTGtGU3JCNDRsZHJJTHZBdnhDQkh6dXFaTTNObmtIaUN5OUtLYnJVcVBIb1MzLTNkWUIwVFZBdFlHMThpcktZbzViSU1Td0wwdFIxcG9sX2Zwa1lON0xneTNmbUZnQ3Q2aE9USi1CdkIzeUVZX0xTOXpPS2…
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUEp1M0EwOWJ3M0d1SzhFSU9SMlZ6T3diZ3pSeVFRdVF5WTNtcE54MU11dnd0dk5lSFNnN29BaF9xQlk0MXJLcExGR2ZodklXWVFFa3dwQmpXbG9jUndQTWVlQ3R3Nmo2VUR6TU1HMF8xUV9HTEw4WVlRSk5VYkEwVkRHXzlESWV3d2UxX0…
BHST — Frequently Asked Questions
What is the current share price of BHST?
As of 2026-08-05 17:25 PDT, BHST trades at $2.26 on NASDAQ/NYSE. Its 52-week range is $1.92 to $12.65.
What is the market capitalisation of BHST?
BHST has a market capitalisation of $51.23M on NASDAQ/NYSE.
What is the P/E ratio of BHST?
BHST trades at a trailing price-to-earnings (P/E) ratio of -3.77. Its price-to-book (P/B) ratio is 2.01.
What is the return on equity (ROE) of BHST?
BHST has a return on equity (ROE) of -43.76%. Its return on capital employed (ROCE) is -13.94%.
Is BHST a good stock to buy?
This page provides a data-driven analysis of BHST, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.